Étiquette : psilocybine

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers, Rainer Kraehenmann et al., 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010   Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]

Lire la suite

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis, Alexander B. Belser et al., 2017

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp   Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]

Lire la suite

Bibliographie : Psilocybes, psilocybine. Usages, ethnologie, psychiatrie, neurophysiologie, pharmacologie, spiritualité, thérapeutique…, Dr Christian Sueur, GRECC, octobre 2019

BIBLIOGRAPHIE : Psilocybes, psilocybine. Dr Christian SUEUR, GRECC, décembre 2019   Psilocybes, psilocybine : généralités ..............................1 Psilocybes : ethnologie ...................................................2 Psilocybine : clinique psychiatrique ..............................4 Psilocybine : pharmacologie ..........................................5 Psilocybine : toxicologie - "effets indésirables" .............7 Psilocybine : neurophysiologie ......................................9 Psilocybine : expériences mystiques .............................13 Psilocybine : thérapie psychédélique ............................15-19    

Lire la suite

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity, Rainer Kraehenmann et al., 2016

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity Rainer Kraehenmann, André Schmidt, Karl Friston, Katrin H. Preller, Erich Seifritz, Franz X. Vollenweider NeuroImage : Clinical, 2016, 11, 53–60 http://dx.doi.org/10.1016/j.nicl.2015.08.009   a b s t r a c t Stimulation of serotonergic neurotransmission by psilocybin has been shown to shift emotional biases away from negative towards positive stimuli. We have recently shown that reduced amygdala activity during threat processing might underlie psilocybin's effect on emotional processing. However, it is still not known whether psilocybin modulates bottom-up or top-down connectivity within the visual-limbic-prefrontal network underlying threat processing.We therefore analyzed our previous fMRI data using [...]

Lire la suite

The psychedelic renaissance : the next trip for psychiatry ?, J. R. Kelly et al., 2019

The psychedelic renaissance : the next trip for psychiatry ? J. R. Kelly, A. Baker, M. Babiker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2019, 1 - 5 doi : 10.1017/ipm.2019.39   Abstract The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological processes involve alterations in brain connectivity, together with altered amygdala and default mode network activity. At the cellular level, psychedelics promote [...]

Lire la suite

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer, Rafael Guimarães dos Santos et al., 2019

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer Rafael Guimarães dos Santos, José Carlos Bouso and Jaime E. C. Hallak BMC Psychiatry, 2019, 19, 321 https://doi.org/10.1186/s12888-019-2288-z   Abstract In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not included. In [...]

Lire la suite

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances, Edward James et al., 2019

Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L Robertshaw & Andrew D Westwell Future Medical Chemistry, 2019 Doi : 10.4155/fmc-2018-0447 C  -  ISSN 1756-8919   “Public and mainstream scientific perceptions of these substances are shifting, and it is not difficult to envision a future in which MDMA and psilocybin play a role in contemporary medicine.” Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy   The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a [...]

Lire la suite

Psilocybin-assisted therapy for depression : How do we advance the field ?, Sally E Meikle et al., 2019

Psilocybin-assisted therapy for depression : How do we advance the field ? Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams, David J Castle Australian & New Zealand Journal of Psychiatry, 2019, 1–7 Doi : 10.1177/0004867419888575   Abstract In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use [...]

Lire la suite

Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This : Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too) An Interview with Richard Yensen, Philip E. Wolfson, 2014

Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This : Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too) An Interview with Richard Yensen Philip E. Wolfson International Journal of Transpersonal Studies, 2014, 33, (2), 160-174.   Richard Yensen was a research fellow at the Maryland Psychiatric Research Center from 1972 to 1976. He studied psychedelic psychotherapy with Stanislav Grof, M.D. and other senior staff. During this time he treated patients with substance abuse disorders, cancer, neurosis, and other health professionals seeking a training experience. Dr. Yensen did his Ph.D. dissertation on the use of MDA in [...]

Lire la suite

Psychedelics and music : neuroscience and therapeutic implications, Frederick S. Barrett et al., 2018

Psychedelics and music : neuroscience and therapeutic implications Frederick S. Barrett, Katrin H. Preller & Mendel Kaelen International Review of Psychiatry, 2018 https://doi.org/10.1080/09540261.2018.1484342   ABSTRACT From the beginning of therapeutic research with psychedelics, music listening has been consistently used as a method to guide or support therapeutic experiences during the acute effects of psychedelic drugs. Recent findings point to the potential of music to support meaning-making, emotionality, and mental imagery after the administration of psychedelics, and suggest that music plays an important role in facilitating positive clinical outcomes of psychedelic therapy. This review explores the history of, contemporary research on, and future directions regarding the use [...]

Lire la suite